Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01719419
Other study ID # PBRC 12014
Secondary ID
Status Withdrawn
Phase N/A
First received October 30, 2012
Last updated December 17, 2015
Start date March 2012
Est. completion date September 2012

Study information

Verified date December 2015
Source Pennington Biomedical Research Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if the drug orlistat (Alli, Xenical) decreases the taste for fat in humans.


Description:

One screening visit and Testing Visits 1 and 2: Approximately 1-2 hours (Fasting - You will have nothing to eat or drink (except water or medications) after midnight before the test visit.) If you qualify for the study, you will return to Pennington Biomedical Research Center for the test visit

- You will be given a questionnaire to screen for allergies or cold symptoms.

- Women will answer a questionnaire based on their menstrual cycle.

- Before eating, you will be given instructions on how to use the study medication. You will swish about 2 teaspoons of a solution in your mouth for 30 seconds and then spit it out (like mouthwash).

- Just before eating, you will be given another brief questionnaire judging your appetite.

- You will be given the test meal. You will be allowed to eat as much or as little as you like during a 20-minute eating period.

- 30 minutes after starting your meal you will be given the brief questionnaire again to judge your appetite.

- You will return in 1 month to complete test visit 2.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 2012
Est. primary completion date September 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Are a healthy male or female,

- Are between 18 to 70 years of age,

- Have a body mass index between 25-35 kg/m2

Exclusion Criteria:

- Are a female who is pregnant or nursing,

- Are a restrained eater (determined using a questionnaire),

- Have any current illnesses such as an infection,

- Have any serious medical problems including kidney, liver, heart or lung disease,

- Use medications known to increase appetite,

- Are taking any medication that has not been on the same dose for at least 30 days,

- Dislike the test food.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
Orlistat
Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.

Locations

Country Name City State
United States Pennington Biomedical Research Center Baton Rouge Louisiana

Sponsors (1)

Lead Sponsor Collaborator
Pennington Biomedical Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Does orlistat decreases the taste for fatty food intake Before eating, you will be given instructions on how to use the study medication. You will swish about 2 teaspoons of a solution in your mouth for 30 seconds and then spit it out (like mouthwash).
Just before eating, you will be given another brief questionnaire judging your appetite.
You will be given the test meal. You will be allowed to eat as much or as little as you like during a 20-minute eating period.
30 minutes after starting your meal you will be given the brief questionnaire again to judge your appetite.
You will return in 1 month to complete test visit 2.
1 month No
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT02805478 - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed NCT03759743 - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject N/A
Completed NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05376865 - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers N/A
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Active, not recruiting NCT03435445 - Online Platform for Healthy Weight Loss (POEmaS) N/A
Enrolling by invitation NCT05576116 - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Active, not recruiting NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Phase 1
Completed NCT03648892 - Brain Dopamine Function in Human Obesity Early Phase 1
Not yet recruiting NCT05751993 - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions N/A
Recruiting NCT02887950 - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause N/A
Terminated NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Completed NCT02899390 - Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes N/A